Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
Latest Information Update: 01 Jul 2024
At a glance
- Drugs TQB-3617 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 04 Jun 2024 Primary results assessing efficacy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 06 Jan 2022 Status changed from not yet recruiting to recruiting.
- 12 Nov 2021 New trial record